The greater efficacy of OCA to prevent cholestasis and maintain biliary flow at lower daily doses of 5 and 15 mg/kg than CDCA (30 mg/kg/day) suggested a mechanism that mediated by its higher FXR agonist activity. Here, NR1H4 is linked to cholestasis.